Any feedback?
Literature summary for 1.1.98.2 extracted from
- Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis (2006), Proc. Natl. Acad. Sci. USA, 103, 431-436.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | PA-824 is a compound for the treatment of tuberculosis (undergoing human trials). PA-824 is a prodrug of the nitroimidazole class, requiring bioreductive activation of an aromatic nitro group to exert an antitubercular effect. Resistance to PA-824 (a nitroimidazo-oxazine) and CGI-17341 (a nitroimidazo-oxazole) is most commonly mediated by loss of a specific glucose-6-phosphate dehydrogenase or its deazaflavin cofactor F420, which together provide electrons for the reductive activation of this class of molecules. Although glucose-6-phosphate dehydrogenase and F420 are necessary for sensitivity to these compounds, they are not sufficient and require additional accessory proteins that directly interact with the nitroimidazole. The sensitivity of Mtb to PA-824 and related compounds is mediated by a protein that is highly specific for subtle structural variations in these bicyclic nitroimidazoles | Mycobacterium tuberculosis |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Mycobacterium tuberculosis | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| FGD1 | - |
Mycobacterium tuberculosis |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
